- Thermo Fisher 1Q adjusted EPS exceeded estimates, with $5.11 vs $5.03 y/y, against an estimate of $4.71.
- Revenue was $10.35 billion, which was a decrease of -3.4% y/y, but beat the estimate of $10.17 billion.
- Life sciences revenue was recorded at $2.29 billion, showing a decline of -13% y/y, but being slightly below the estimate of $2.36 billion.
- Revenue from analytical instruments came in at $1.69 billion, marking a slight drop (-2.1% y/y), however exactly meeting the estimated figure.
- Specialty diagnostics revenue was consistent with the previous year’s figure of $1.11 billion, outdoing an estimate of $1.08 billion.
- Lab products & services revenue stood at $5.72 billion, down -0.7% y/y, but surpassing the estimate of $5.48 billion.
- Foreign currency had no impact on sales this time, as opposed to the -2% y/y, and against the estimated -0.74%.
- Adjusted operating income was observed at $2.28 billion, showing a slight decrease of -2.2% y/y, but still managing to outdo the estimate of $2.12 billion.
- Eliminations revenue experienced an increase, -$460 million, +7.3% y/y, but beating the estimated -$462.9 million.
- Thermo Fisher is enhancing its full year revenue and adjusted EPS guidance in consideration of a robust operational performance.
- Notably, of all analyst ratings, 19 recommended buying, 7 suggested holding, and none supported selling.
Thermo Fisher Scientific Inc on Smartkarma
Multiple independent analysts on Smartkarma, such as Baptista Research, are providing valuable insight into Thermo Fisher Scientific Inc. In a report titled “Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! – Financial Forecasts,” Baptista Research underscores the company’s strong execution and operational discipline in 2023. Thermo Fisher Scientific reported impressive figures, including a revenue of $42.9 billion, adjusted operating income of $9.81 billion, and adjusted earnings per share of $21.55. The company credits these accomplishments to its focus on delivering short-term performance while fortifying its long-term competitive position.
A look at Thermo Fisher Scientific Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Thermo Fisher Scientific Inc, a manufacturer of scientific instruments and consumables, appears to have a mixed long-term outlook based on Smartkarma Smart Scores. While the company scores well in momentum, resilience, and growth factors, its value and dividend scores are more moderate. This suggests that Thermo Fisher Scientific Inc is showing positive momentum in the market, with a solid ability to withstand economic challenges and promising growth potential.
Thermo Fisher Scientific, Inc. provides a wide range of scientific instruments, consumables, and chemicals to various sectors including pharmaceutical and biotech companies, hospitals, universities, and government agencies. With its strong emphasis on innovation and growth, the company seems well-positioned for continued success in the industry, supported by its solid performance in momentum, resilience, and growth according to Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
